Second Quarter 2025 Results / Half-Year Financial Report

Bayer Q2 2025 Media Update

Group sales at 10.739 billion euros (Fx & p adj. plus 0.9 percent)
EBITDA before special items at 2.105 billion euros (minus 0.3 percent)
Crop Science posts higher sales (Fx & p adj.), earnings up significantly
Pharmaceuticals sales at prior-year level (Fx & p adj.), earnings down substantially
Consumer Health reports stable sales (Fx & p adj.) and higher earnings
Core earnings per share rise 30.9 percent to 1.23 euros
Net income at minus 199 million euros – special charges for litigations partially offset by impairment loss reversals at Crop Science
Free cash flow declines to 125 million euros
Net financial debt at 33.274 billion euros
Upgraded guidance for currency-adjusted sales and earnings, negative currency effects anticipated